ROCKVILLE, Md.-Rexahn Pharmaceuticals, Inc. (NYSE Amex:RNN), a clinical stage biopharmaceutical company developing first-in-class oncology and CNS therapeutics, today announced that it will present at the BIO 2009 International Convention at the Georgia World Congress Center (Room 314, Building A, Level 3) in Atlanta, GA on Wednesday, May 20, 2009 at 3:00 PM ET.
Rexahn’s Senior Business Development Director, Wendy Tsai, and Chief Business Officer, Rick Soni, will provide a strategic business update of Rexahn’s recent clinical and financing milestones, opportunities for licensing and alliances, and an overview of its R&D pipeline.
Rexahn currently has three drug candidates in Phase II clinical trials - Archexin, Serdaxin, and Zoraxel - all potential best in class therapeutics, and a robust pipeline of preclinical compounds to treat multiple cancers and CNS disorders.
If you plan on attending the conference, and would like to arrange a one-on-one meeting with management, please contact Wendy Tsai at 240-268-5300 x314.
No comments:
Post a Comment